FULC Earnings Prediction
The chart below shows how FULC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, FULC sees a +6.38% change in stock price 10 days leading up to the earnings, and a -3.61% change 10 days following the report. On the earnings day itself, the stock moves by +3.45%. This data can give you a slight idea of what to expect for the next quarter's release.
FULC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
-100.00%
-100.00%
Gross Margin
--
--
--
Operating Margin
-0.51%
-99.99%
-100.78%
Net Margin
8.55%
100.27%
-87.66%
EPS
-0.35
-10.26%
-140.23%
No Data Available
FULC Earnings Analysis
Fulcrum Therapeutics, Inc. Common Stock Corporation (FULC.O) Earnings Conference Call
Positive
Cash and Marketable Securities Increase: As of September 30, 2024, cash, cash equivalents and marketable securities were $257.2 million compared to $236.2 million as of December 31, 2023.
Cash Position Increase: The increase in our cash position is due to the $80 million upfront payment that we received from Sanofi in the second quarter, partially offset by cash used to fund our operating activities in 2024.
R&D Expense Decrease: Research and development expenses were $14.6 million for the third quarter of 2024 compared to $18.2 million for the third quarter of 2023, reflecting a decrease of $3.6 million primarily due to the global development cost sharing reimbursement under our collaboration agreement with MyoKardia during the fourth quarter of 2023.
Administrative Expense Reduction: General and administrative expenses were $8.4 million for the third quarter of 2024 compared to $10 million for the third quarter of 2023, a decrease of $1.6 million primarily due to decreased employee compensation costs as a result of our reduction in workforce implemented in the third quarter of 2024.
Cash Projections and Burn Rate: We expect to end 2024 with approximately $240 million of cash, cash equivalents and marketable securities, and we expect that in 2025, our cash burn will be approximately $55 million to $65 million.
Negative
Net Loss Comparison: The company reported a net loss of $21.7 million for the third quarter of 2024 compared to a net loss of $24 million for the same period in 2023, indicating a continued struggle to achieve profitability.
R&D Expense Decrease: Research and development expenses were $14.6 million for the third quarter of 2024, down from $18.2 million in the same quarter of 2023, reflecting a reduction in investment in innovation.
Cash and Securities Increase: Cash, cash equivalents, and marketable securities increased to $257.2 million as of September 30, 2024, from $236.2 million as of December 31, 2023, primarily due to an $80 million upfront payment, but this was partially offset by cash used to fund operating activities in 2024.
Collaboration Revenue Decline: The company had no collaboration revenue in the third quarter of 2024, compared to $0.8 million for the third quarter of 2023, highlighting a significant decline in partnership activities.
Rising Administrative Expenses: General and administrative expenses rose to $8.4 million for the third quarter of 2024, compared to $10 million for the same quarter of 2023, indicating ongoing cost management challenges.
FULC FAQs
How does FULC typically perform around its earnings report dates?
Is Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
FULC Earning Call Sentiment
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
FULC.O
6.53%Positive
The earnings call presents a mixed picture. The collaboration with Sanofi and a strong cash position are positives, but the company faces challenges such as workforce reduction, competition, and expected cash burn. The Q&A session reveals regulatory hurdles and unclear timelines, adding uncertainty. Despite a decrease in net loss, the lack of collaboration revenue and uncertain guidance temper optimism. Overall, the positives and negatives balance out, leading to a neutral outlook for the stock price over the next two weeks.
